<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02062580</url>
  </required_header>
  <id_info>
    <org_study_id>MV-00-9-900-01871</org_study_id>
    <nct_id>NCT02062580</nct_id>
  </id_info>
  <brief_title>Early Versus Delayed BCG Vaccination of HIV-exposed Infants</brief_title>
  <official_title>Influence of BCG Immunization on Immune Responses and Disease Progression in South African HIV Exposed and Infected Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seattle Biomedical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Stellenbosch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cape Town</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In sub-Saharan Africa (SSA), more than 300,000 babies with HIV die each year. HIV-infected
      children develop AIDS and die faster in SSA than those in developed countries. Bacille
      Calmette-Guerin (BCG) vaccine is given to infants at birth in SSA to protect them from severe
      forms of TB. BCG is known to cause immune cells to be active and replicate faster. The immune
      system of neonates also responds differently to BCG that to other vaccines and infections. We
      hypothesize that the routine immunization of neonates with BCG contributes to generalized
      immune activation in HIV-exposed infants resulting in skewed immune responses to vaccines and
      infections and increased rates of disease progression in those infants that become
      HIV-infected. However, delaying BCG until HIV testing is completed would result in
      operational difficulties, and may not induce the appropriate immune response. Delayed BCG
      would also render many HIV-exposed uninfected infants at high risk for disseminated TB. We
      plan to assess immune cells in infants to determine the impact of the timing of BCG
      vaccination on immune responses to tuberculosis (TB) and other vaccines. We will also compare
      the immune activation and disease progression of those infants that become HIV-infected in
      the BCG or control arms. Our results will provide key insights into the effect of BCG
      vaccination on immune responses to HIV as well as inform the optimal timing of BCG
      vaccination for HIV-exposed infants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T Cell Activation</measure>
    <time_frame>at 6 weeks</time_frame>
    <description>Percentage of all CD4+ T cells expressing HLADR (NOT BCG-specific activation as in Tchakoute et al and as in secondary outcome). The n is smaller than the enrollment number as some participants were lost to follow-up, some were excluded due to HIV infection etc, and some samples did not have sufficient cells to analyse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaccine Immunogenicity</measure>
    <time_frame>6 weeks after BCG vaccination</time_frame>
    <description>Percent of CD4+ T cells expressing Ki67 after stimulation in vitro with BCG.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>HIV Exposure</condition>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Delayed BCG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BCG delayed to 8 weeks of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early BCG</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>BCG at birth; standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG</intervention_name>
    <arm_group_label>Delayed BCG</arm_group_label>
    <arm_group_label>Early BCG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy neonate

          -  Maternal HIV

          -  &gt; 36 weeks gestation

          -  Birth weight &gt; 2.4kg

          -  Remaining in area 4 months

        Exclusion Criteria:

          -  Complications during pregnancy and delivery

          -  Household TB contacts
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather B Jaspan, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cape Town</affiliation>
  </overall_official>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2014</study_first_submitted>
  <study_first_submitted_qc>February 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2014</study_first_posted>
  <results_first_submitted>October 25, 2016</results_first_submitted>
  <results_first_submitted_qc>January 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 15, 2017</results_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cape Town</investigator_affiliation>
    <investigator_full_name>Dr Heather Jaspan</investigator_full_name>
    <investigator_title>Senior Lecturer</investigator_title>
  </responsible_party>
  <keyword>Vaccine immunogenicity</keyword>
  <keyword>Immune activation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Delayed BCG</title>
          <description>BCG delayed to 8 weeks of age
BCG</description>
        </group>
        <group group_id="P2">
          <title>Early BCG</title>
          <description>BCG at birth; standard of care
BCG</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Delayed BCG</title>
          <description>BCG delayed to 8 weeks of age
BCG</description>
        </group>
        <group group_id="B2">
          <title>Early BCG</title>
          <description>BCG at birth; standard of care
BCG</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="78"/>
            <count group_id="B3" value="149"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Median gestational age, in weeks</description>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" lower_limit="38" upper_limit="40"/>
                    <measurement group_id="B2" value="40" lower_limit="39" upper_limit="40"/>
                    <measurement group_id="B3" value="39.5" lower_limit="38" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>count of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birth weight</title>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.15" lower_limit="2.85" upper_limit="3.3"/>
                    <measurement group_id="B2" value="3.12" lower_limit="2.8" upper_limit="3.4"/>
                    <measurement group_id="B3" value="3.13" lower_limit="2.9" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maternal CD4 T cell count</title>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="358" lower_limit="254" upper_limit="548"/>
                    <measurement group_id="B2" value="366" lower_limit="271" upper_limit="477"/>
                    <measurement group_id="B3" value="362" lower_limit="263" upper_limit="513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Breastfed</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>T Cell Activation</title>
        <description>Percentage of all CD4+ T cells expressing HLADR (NOT BCG-specific activation as in Tchakoute et al and as in secondary outcome). The n is smaller than the enrollment number as some participants were lost to follow-up, some were excluded due to HIV infection etc, and some samples did not have sufficient cells to analyse.</description>
        <time_frame>at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Delayed BCG</title>
            <description>BCG delayed to 8 weeks of age
BCG</description>
          </group>
          <group group_id="O2">
            <title>Early BCG</title>
            <description>BCG at birth; standard of care
BCG</description>
          </group>
        </group_list>
        <measure>
          <title>T Cell Activation</title>
          <description>Percentage of all CD4+ T cells expressing HLADR (NOT BCG-specific activation as in Tchakoute et al and as in secondary outcome). The n is smaller than the enrollment number as some participants were lost to follow-up, some were excluded due to HIV infection etc, and some samples did not have sufficient cells to analyse.</description>
          <units>percentage of CD4+ T cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1" upper_limit="2.8"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.8" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Immunogenicity</title>
        <description>Percent of CD4+ T cells expressing Ki67 after stimulation in vitro with BCG.</description>
        <time_frame>6 weeks after BCG vaccination</time_frame>
        <population>Analysis population n is smaller than enrollment numbers as we calculated that that only 28 were needing in each arm to detect a difference.</population>
        <group_list>
          <group group_id="O1">
            <title>Delayed BCG</title>
            <description>BCG delayed to 8 weeks of age
BCG</description>
          </group>
          <group group_id="O2">
            <title>Early BCG</title>
            <description>BCG at birth; standard of care
BCG</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Immunogenicity</title>
          <description>Percent of CD4+ T cells expressing Ki67 after stimulation in vitro with BCG.</description>
          <population>Analysis population n is smaller than enrollment numbers as we calculated that that only 28 were needing in each arm to detect a difference.</population>
          <units>percentage of Ki67% CD4+ T cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" lower_limit="4.7" upper_limit="28.5"/>
                    <measurement group_id="O2" value="20.5" lower_limit="10" upper_limit="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Delayed BCG</title>
          <description>BCG delayed to 8 weeks of age
BCG</description>
        </group>
        <group group_id="E2">
          <title>Early BCG</title>
          <description>BCG at birth; standard of care
BCG</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Blocked nostrils</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="71"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash- nonspecific</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="71"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Diaper Rash</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Heather Jaspan</name_or_title>
      <organization>University of Cape Town and University of Washington</organization>
      <phone>+2721 4066823</phone>
      <email>hbjaspan@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

